Variants of MIRNA146A rs2910164 and MIRNA499 rs3746444 are associated with the development of cutaneous leishmaniasis caused by Leishmania guyanensis and with plasma chemokine IL-8.


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
09 2021
Historique:
received: 24 05 2021
accepted: 07 09 2021
revised: 30 09 2021
pubmed: 21 9 2021
medline: 15 12 2021
entrez: 20 9 2021
Statut: epublish

Résumé

Leishmania are intracellular protozoan parasites that cause a wide spectrum of clinical manifestations in genetically susceptible individuals with an insufficient or balanced Th1 immune response to eliminate the parasite. MiRNAs play important regulatory role in numerous biological processes including essential cellular functions. miR146-a acts as an inhibitor of interleukin 1 receptor associated kinase 1 (IRAK1) and tumour necrosis factor (TNF) receptor associated factor 6 (TRAF6) present in the toll-like receptors pathway while miR499a modulates TGF-β and TNF signalling pathways. Here, we investigated whether MIRNA146A rs2910164 and MIRNA499 rs3746444 variants are associated with the development of L. guyanensis (Lg)-cutaneous leishmaniasis (CL). The variants MIR146A rs2910164 and MIR499A rs3746444 were assessed in 850 patients with Lg-CL and 891 healthy controls by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). Plasma cytokines were measured using the BioPlex assay. Carriers of rs2910164 CC genotype have 30% higher odds of developing CL (ORadjage/sex = 1.3 [95%CI 0.9-1.8]; Padjage/sex 0.14) compared to individuals with the genotype GG (ORadjage/sex = 0.77 [95%CI 0.56-1.0]; Padjage/sex 0.14) if exposed to Lg-infection. Heterozygous GC individuals also showed lower odds of developing CL (ORadjage/sex = 0.77 [95%CI 0.5-1.1]; Padjage/sex 0.09). Homozygosity for the allele C is suggestive of an association with the development of Lg-CL among exposed individuals to Lg-infection. However, the odds of developing CL associated with the CC genotype was evident only in male individuals (ORadjage = 1.3 [95% CI = 0.9-2.0]; Padjage = 0.06). Individuals homozygous for the G allele tend to have higher plasma IL-8 and CCL5. Similarly, for the MIR499A rs3746444, an association with the G allele was only observed among male individuals (OR = 1.4 [1.0-1.9]; P = 0.009). In a dominant model, individuals with the G allele (GG-GA) when compared to the AA genotype reveals that carriers of the G allele have 40% elevated odds of developing Lg-CL (ORadjage = 1.4 [1.1-1.9]). Individuals with the GG genotype have higher odds of developing Lg-CL (ORadjage/sex = 2.0 [95%CI 0.83-5.0]; Padjage = 0.01. Individuals homozygous for the G allele have higher plasma IL-8. Genetic combinations of both variants revealed that male individuals exposed to Lg bearing three or four susceptible alleles have higher odds of developing Lg-CL (OR = 2.3 [95% CI 1.0-4.7]; p = 0.017). Both MIR146A rs2910164 and MIR499A rs3746444 are associated with the development of Lg-CL and this association is prevalent in male individuals.

Identifiants

pubmed: 34543271
doi: 10.1371/journal.pntd.0009795
pii: PNTD-D-21-00753
pmc: PMC8483412
doi:

Substances chimiques

Cytokines 0
Interleukin-8 0
Intracellular Signaling Peptides and Proteins 0
MicroRNAs 0
Tifab protein, human 0
IRAK1 protein, human EC 2.7.11.1
Interleukin-1 Receptor-Associated Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0009795

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Sci Rep. 2017 Mar 09;7:44141
pubmed: 28276497
Mol Med Rep. 2013 Jan;7(1):287-91
pubmed: 23138379
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Hum Immunol. 2011 Jul;72(7):598-602
pubmed: 21524676
Front Aging Neurosci. 2018 Mar 28;10:82
pubmed: 29643803
Biol Rev Camb Philos Soc. 2018 Nov;93(4):1955-1986
pubmed: 29797774
Mol Diagn Ther. 2016 Jun;20(3):279-95
pubmed: 27002721
Emerg Infect Dis. 2003 Jun;9(6):727-9
pubmed: 12781016
Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv104-5
pubmed: 16239376
Mediators Inflamm. 2014;2014:916202
pubmed: 24701036
PLoS One. 2012;7(2):e30049
pubmed: 22363415
J Infect Dis. 2009 Jul 1;200(1):75-8
pubmed: 19476435
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9184-9
pubmed: 21576471
Am J Trop Med Hyg. 2015 Dec;93(6):1208-13
pubmed: 26483119
J Clin Microbiol. 2004 May;42(5):2294-7
pubmed: 15131217
Genes Immun. 2012 Apr;13(3):268-74
pubmed: 22218224
Immunity. 2015 Jul 21;43(1):52-64
pubmed: 26163372
PLoS One. 2014 Feb 26;9(2):e89930
pubmed: 24587132
PLoS One. 2017 Jun 29;12(6):e0179850
pubmed: 28662100
Infect Immun. 2004 Aug;72(8):4918-23
pubmed: 15271961
Cytokine. 2019 Nov;123:154788
pubmed: 31357078
Arthritis Rheum. 2009 Apr;60(4):1065-75
pubmed: 19333922
J Immunol. 1993 Oct 1;151(7):3682-92
pubmed: 8397259
J Immunol. 2009 Mar 1;182(5):3039-46
pubmed: 19234200
Genet Test Mol Biomarkers. 2015 Aug;19(8):424-30
pubmed: 26053525
PLoS One. 2019 Aug 8;14(8):e0220572
pubmed: 31393896
Mol Biol Rep. 2012 Apr;39(4):4571-9
pubmed: 21947843
Proc Natl Acad Sci U S A. 2008 May 20;105(20):7269-74
pubmed: 18474871
Medicine (Baltimore). 2019 Feb;98(6):e14401
pubmed: 30732186
Parasite Immunol. 2018 Mar;40(3):
pubmed: 29272044
Arthritis Res Ther. 2018 Mar 15;20(1):45
pubmed: 29544526
Oncogene. 2008 Sep 18;27(42):5643-7
pubmed: 18504431
Immunol Lett. 2014 Oct;161(2):179-83
pubmed: 24412597
Cell Host Microbe. 2013 Mar 13;13(3):277-88
pubmed: 23498953
Clin Infect Dis. 2020 Jul 11;71(2):274-281
pubmed: 31722386
J Immunol Res. 2019 Dec 1;2019:2603730
pubmed: 31871953
J Clin Microbiol. 2003 Jul;41(7):3147-53
pubmed: 12843055
Indian J Clin Biochem. 2018 Jan;33(1):96-101
pubmed: 29371777
Mol Biol Rep. 2011 Nov;38(8):4913-9
pubmed: 21181275
Arthritis Res Ther. 2008;10(4):R101
pubmed: 18759964
Nat Rev Genet. 2010 Sep;11(9):597-610
pubmed: 20661255
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Gene. 2018 Jan 15;640:66-72
pubmed: 29032146
Carcinogenesis. 2008 Nov;29(11):2126-31
pubmed: 18711148
J Neurooncol. 2011 Dec;105(3):639-46
pubmed: 21744077
J Exp Med. 2011 Jun 6;208(6):1189-201
pubmed: 21555486
Oncotarget. 2017 Jan 3;8(1):393-407
pubmed: 27880723
Open Biol. 2017 Apr;7(4):
pubmed: 28381629
Rev Assoc Med Bras (1992). 2018 Mar;64(3):281-289
pubmed: 29641786
Front Immunol. 2015 Jul 08;6:334
pubmed: 26217335
Tohoku J Exp Med. 2014;233(2):89-94
pubmed: 24850191
Sci Rep. 2019 Dec 27;9(1):19841
pubmed: 31882833
Cancer Res. 2010 Apr 1;70(7):2789-98
pubmed: 20332227
Front Immunol. 2014 Nov 21;5:578
pubmed: 25484882
ACS Omega. 2020 May 18;5(21):12516-12526
pubmed: 32548436
Sci Rep. 2020 Feb 26;10(1):3508
pubmed: 32103099
Parasite Immunol. 2015 Jan;37(1):43-51
pubmed: 25376316
Dermatol Clin. 2015 Jul;33(3):579-93
pubmed: 26143433
PLoS One. 2015 Apr 01;10(4):e0121918
pubmed: 25830862
Acta Cardiol. 2018 Apr;73(2):131-140
pubmed: 28786773
Cell Physiol Biochem. 2018;48(1):149-157
pubmed: 30001553
J Invest Dermatol. 2014 Jul;134(7):1931-1940
pubmed: 24670381
Parasit Vectors. 2016 Nov 29;9(1):612
pubmed: 27899126
PLoS One. 2014 Nov 14;9(11):e112410
pubmed: 25397678
Clin Res Cardiol. 2012 Apr;101(4):289-96
pubmed: 22159951
PLoS Pathog. 2021 Feb 25;17(2):e1009343
pubmed: 33630975
Int J Mol Cell Med. 2015 Winter;4(1):40-5
pubmed: 25815281
Clin Cancer Res. 2011 Jul 1;17(13):4277-84
pubmed: 21632853
PLoS One. 2015 Apr 02;10(4):e0122055
pubmed: 25836258
BMC Genomics. 2008 May 21;9:238
pubmed: 18495030
PLoS Pathog. 2013 Mar;9(3):e1003243
pubmed: 23555256
PLoS Negl Trop Dis. 2014 Sep 04;8(9):e3099
pubmed: 25187983
J Allergy Clin Immunol. 2017 Feb;139(2):550-561
pubmed: 27568078
Lancet. 2018 Sep 15;392(10151):951-970
pubmed: 30126638
Onco Targets Ther. 2019 Aug 08;12:6245-6252
pubmed: 31496728
J Biol Chem. 2009 Dec 11;284(50):34590-9
pubmed: 19840932
Respir Res. 2017 Sep 8;18(1):169
pubmed: 28886711
J Immunol. 2008 Apr 15;180(8):5689-98
pubmed: 18390754
Front Immunol. 2018 Jun 25;9:1377
pubmed: 29988529
Leukemia. 2017 Dec;31(12):2732-2741
pubmed: 28484267
J Immunol. 2009 Aug 1;183(3):2150-8
pubmed: 19596990
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6
pubmed: 16885212
Nat Med. 2013 Jul;19(7):909-15
pubmed: 23749230
BMC Med Genet. 2018 Mar 27;19(1):48
pubmed: 29587639
J Infect Dis. 2021 Jun 17;:
pubmed: 34139757

Auteurs

Tirza Gabrielle Ramos de Mesquita (TGR)

Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil.
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.

José do Espírito Santo Junior (JDES)

Programa de Pós-Graduação em Imunologia Básica e Aplicada, Instituto de Ciências Biológicas, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil.
Faculdade de Medicina Nilton Lins, Universidade Nilton Lins, Manaus, Amazonas, Brazil.

Thais Carneiro de Lacerda (TC)

Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil.
Faculdade de Medicina Nilton Lins, Universidade Nilton Lins, Manaus, Amazonas, Brazil.

Krys Layane Guimarães Duarte Queiroz (KLGD)

Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.

Cláudio Marcello da Silveira Júnior (CMDS)

Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.

José Pereira de Moura Neto (JPM)

Faculdade de Ciências Farmacêuticas, Universidade Federal do Amazonas, Manaus, Amazonas, Brazil.

Lissianne Augusta Matos Gomes (LAM)

Faculdade de Medicina Nilton Lins, Universidade Nilton Lins, Manaus, Amazonas, Brazil.

Mara Lúcia Gomes de Souza (MLG)

Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.

Marcus Vinitius de Farias Guerra (MVF)

Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil.
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
Genomic Health Surveillance Network: Optimization of Assistance and Research in The State of Amazonas-REGESAM, Manaus, Amazonas, Brazil.

Rajendranath Ramasawmy (R)

Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do Amazonas, Manaus, Amazonas, Brazil.
Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
Faculdade de Medicina Nilton Lins, Universidade Nilton Lins, Manaus, Amazonas, Brazil.
Genomic Health Surveillance Network: Optimization of Assistance and Research in The State of Amazonas-REGESAM, Manaus, Amazonas, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH